Health-Related Quality of Life With Pembrolizumab+Chemotherapy Versus Placebo+Chemotherapy for Advanced Triple-Negative Breast Cancer: KEYNOTE-355.

David W CesconPeter SchmidHope S RugoSeock-Ah ImMastura Md YusofCarlos GallardoOleg LipatovCarlos H BarriosJose Perez-GarciaHiroji IwataNorikazu MasudaMarco Torregroza OteroErhan GokmenSherene LoiAmin HaideraliXuan ZhouZifang GuoAllison Martin NguyenJavier Cortes

Published in: Journal of the National Cancer Institute (2023)

Together with the efficacy and safety findings, PRO results from KEYNOTE-355 support pembrolizumab plus chemotherapy as a standard of care for patients with advanced TNBC with tumor PD-L1 (CPS ≥10).

Keyphrases

locally advanced
healthcare
advanced non small cell lung cancer
palliative care
squamous cell carcinoma
phase ii
chemotherapy induced
quality improvement
radiation therapy
randomized controlled trial
pain management
anti inflammatory
health insurance
tyrosine kinase